NCT07844603CompletedPhase 2
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME): A Randomized Pilot Study
Source: ClinicalTrials.gov · Last updated 28 Sept 2026
Brief summary (registry, in English)
Stroke is a common cause of disability. The most common type of stroke, an ischemic stroke, is caused by a blood vessel in the brain getting blocked by a clot. When this happens, part of the brain is damaged because it is not getting the blood supply it needs. To treat this type of stroke, doctors give medication and/or do a procedure to remove the blockage and restore blood supply to the brain. Unfortunately, patients who have had an ischemic stroke are at higher risk of having another ischemic stroke. This risk is highest in the first 21 days after a stroke. Currently, doctors give patients the medication aspirin every day, starting 24 hours after stroke treatment, to prevent recurrent strokes. However, some studies have shown that giving another medication, clopidogrel, in addition to aspirin, is safe and may work better than aspirin alone at preventing repeat strokes. Both aspirin and clopidogrel are a type of medication called an antiplatelet that prevents clots from forming in the blood. When both medications are given together, it is called dual antiplatelet treatment. The main risk of antiplatelet medications is bleeding. This research aims to study the safety and feasibility of using dual antiplatelet treatment to prevent recurrent strokes. Patients who have received treatment for an ischemic stroke will first be screened to rule out patients at high risk of bleeding. Following informed consent, patients at low risk of bleeding will be enrolled in the study 24 hours after their initial stroke treatment. Patients will be randomly assigned to either take aspirin alone or aspirin and clopidogrel for 21 days for recurrent stroke prevention. The study team will then follow patients for three months after treatment to collect information about their recovery and assess differences between the two groups.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- First submitted
- 22 Sept 2026
- Start date
- 2 Sept 2025
- Primary completion date
- 13 Jul 2026
- Lead sponsor
- University of Alberta
- Diseases
- Stroke
- NCT number
- NCT07844603
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 3
- From 2 Sept 2025 to the primary completion date, 13 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Evidence-based indication for dual antiplatelet therapy
- Planned surgical intervention in the next 90 days includes but is not limited to carotid endarterectomy, where dual antiplatelet is not indicated, and carotid stenting, where single antiplatelet is not used.
- Intracranial or spinal cord surgery within three months;
- Gastrointestinal or urinary tract hemorrhage within the previous 21 days;
Other illness
- Any known disorder associated with a significantly increased risk of bleeding
- History of intracranial or subarachnoid hemorrhage
- Index stroke is caused by infective endocarditis, dissection, systematic or central nervous system vasculitis
- History of active malignancy being treated or life expectancy ≤ 90 days
- Allergy to clopidogrel or aspirin
- The presence of a major co-morbid illness that would make it unlikely that the participant will be able to complete follow-up
Lab values
- Coagulation disorder, thrombocytopenia \<100, 000/mm3, and Prothrombin time INR ≥1.8
Other
- Post-reperfusion CT scan ASPECT score \<8.
- Anticoagulation is required for any indication other than DVT prophylaxis
- Intracranial tumour, arteriovenous malformation or aneurysm;
- Pregnancy
- Participation in another clinical trial.
Who the study is looking for
- Participants must be \>18 years of age at the time of randomization
- Acute non-cardioembolic ischemic stroke in the anterior circulation treated with reperfusion therapy defined as intravenous thrombolysis (IVT) and/or endovascular thrombectomy (EVT)
- Time from end of acute reperfusion therapy to randomization ≤ 24 hours
- Mild to moderate deficit defined as a National Institute of Health stroke scale of ≤11 at the time of randomization
- At least one non-contrast CT scan completed post reperfusion therapy and prior to randomization without any hemorrhage (including hemorrhagic infarction) and/or contrast extravasation.
- Premorbid mRS less than or equal to 2
- Signed informed consent from the patient or legally authorized representative
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alberta Hospital Coordinator of this site? Confirm its status | Edmonton | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.